Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:08
07/02/20
07/02
18:08
07/02/20
18:08
GSK

GlaxoSmithKline

$41.22 /

+0.35 (+0.86%)

, UIHC

United Insurance

$7.51 /

+0.03 (+0.40%)

, REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
UIHC United Insurance
$7.51 /

+0.03 (+0.40%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
UIHC United Insurance
$7.51 /

+0.03 (+0.40%)

01/06/20 Wells Fargo
United Insurance downgraded to Underweight at Wells Fargo
01/06/20 Wells Fargo
United Insurance downgraded to Underweight from Equal Weight at Wells Fargo
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

  • 27
    May
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

GSK GlaxoSmithKline
$41.22 /

+0.35 (+0.86%)

Hot Stocks
Regeneron falls 3.5% after ph.3 data on Kevzara in Covid patients  16:33
07/02/20
07/02
16:33
07/02/20
16:33
REGN

Regeneron

$622.75 /

+13.53 (+2.22%)

 
ShowHide Related Items >><<
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

  • 27
    May
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

Hot Stocks
Regeneron/Sanofi's ph3 trial of Kevzara in COVID did not meet endpoints » 16:32
07/02/20
07/02
16:32
07/02/20
16:32
SNY

Sanofi

$51.65 /

+0.37 (+0.72%)

, REGN

Regeneron

$622.75 /

+13.53 (+2.22%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced that the U.S. Phase 3 trial of Kevzara or sarilumab, 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone. Minor positive trends were observed in the primary pre-specified analysis group that did not reach statistical significance, and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi-organ dysfunction syndrome and hypotension. Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara of 800 mg.

ShowHide Related Items >><<
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

  • 27
    May
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

Wednesday
Recommendations
Applied Genetic may attract Sanofi takeover interest, says Roth Capital » 13:06
07/01/20
07/01
13:06
07/01/20
13:06
AGTC

Applied Genetic

$5.72 /

+0.17 (+3.06%)

, SNY

Sanofi

$51.27 /

+0.19 (+0.37%)

Applied Genetic…

Applied Genetic Technologies (AGTC) recently announced significant advancements to its proprietary AAV gene therapy manufacturing platform, which "exceeds the performance and economics of many others," Roth Capital analyst Zegbeh Jallah tells investors in a research note. Further, Investigational New Drug enabling studies for more indications beyond rare genetic retinal diseases are expected to begin during the second half of 2020 and could put Applied Genetic "into the running for M&A interest" from Sanofi (SNY), adds the analyst. Jallah believes the company's manufacturing advancements position it to potentially attract takeover or partnering interest from large pharma. The analyst keeps a Buy rating on Applied Genetic Technologies with a $25 price target. The stock is up 6% to $5.88 in afternoon trading following the analyst note.

ShowHide Related Items >><<
SNY Sanofi
$51.27 /

+0.19 (+0.37%)

AGTC Applied Genetic
$5.72 /

+0.17 (+3.06%)

AGTC Applied Genetic
$5.72 /

+0.17 (+3.06%)

06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
SNY Sanofi
$51.27 /

+0.19 (+0.37%)

06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
SNY Sanofi
$51.27 /

+0.19 (+0.37%)

AGTC Applied Genetic
$5.72 /

+0.17 (+3.06%)

  • 07
    Feb
SNY Sanofi
$51.27 /

+0.19 (+0.37%)

SNY Sanofi
$51.27 /

+0.19 (+0.37%)

SNY Sanofi
$51.27 /

+0.19 (+0.37%)

Recommendations
Regeneron price target raised to $675 from $625 at Oppenheimer » 08:11
07/01/20
07/01
08:11
07/01/20
08:11
REGN

Regeneron

$623.65 /

+13.41 (+2.20%)

Oppenheimer analyst…

Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $675 from $625 and keeps an Outperform rating on the shares. The analyst continues to highlight Regeneron as one of his top biotech names. However, with the stock up about 67% year-to-date, he acknowledges that performance in the second half of 2020 could be accompanied by greater volatility. Singh would argue that, with potential Eylea competition receding, and Dupixent revenues continuing to grow, mid/long-term sales/earnings momentum should continue.

ShowHide Related Items >><<
REGN Regeneron
$623.65 /

+13.41 (+2.20%)

REGN Regeneron
$623.65 /

+13.41 (+2.20%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
REGN Regeneron
$623.65 /

+13.41 (+2.20%)

  • 27
    May
REGN Regeneron
$623.65 /

+13.41 (+2.20%)

REGN Regeneron
$623.65 /

+13.41 (+2.20%)

REGN Regeneron
$623.65 /

+13.41 (+2.20%)

Monday
Hot Stocks
Kiniksa says Phase 3 trial of rilonacept meets efficacy endpoints » 07:22
06/29/20
06/29
07:22
06/29/20
07:22
KNSA

Kiniksa

$23.04 /

-2.19 (-8.68%)

, REGN

Regeneron

$611.30 /

-8.81 (-1.42%)

Kiniksa Pharmaceuticals…

Kiniksa Pharmaceuticals (KNSA) reported data from RHAPSODY, a pivotal Phase 3 trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling, in recurrent pericarditis. RHAPSODY met its prespecified primary and all major secondary efficacy endpoints, showing that rilonacept improved clinically meaningful outcomes associated with the unmet medical need in recurrent pericarditis, a painful and debilitating autoinflammatory disease. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis in 2019, and Kiniksa expects to submit a Supplemental Biologics License Application later this year. RHAPSODY is a global, randomized withdrawal design, pivotal Phase 3 clinical trial of rilonacept in recurrent pericarditis. The trial's primary analysis population included 61 actively symptomatic recurrent pericarditis patients who were failing standard of care treatment, including nonsteroidal anti-inflammatory drugs, colchicine, or corticosteroids, initiated rilonacept treatment during a run-in period, discontinued background medications, and achieved and maintained clinical response on rilonacept monotherapy. Clinical responders were randomized 1:1 to receive continued weekly rilonacept or placebo in a blinded manner in the randomized withdrawal period. The primary efficacy endpoint of time-to-first adjudicated pericarditis recurrence in the randomized withdrawal period was highly statistically significant. Median time to pericarditis recurrence for rilonacept recipients in the randomized withdrawal period could not be estimated due to the low number of recurrences in the rilonacept treatment arm. The median time-to-recurrence for placebo recipients was 8.6 weeks. Rilonacept recipients experienced a 96% reduction in risk of recurrent pericarditis events. All major secondary efficacy endpoints in the randomized withdrawal period were also highly statistically significant. 81% of rilonacept recipients maintained clinical response at Week 16 of the randomized withdrawal period, compared to 20% of placebo recipients. Consistent results were observed at Week 8 and Week 24 and were also highly statistically significant. The proportion of rilonacept recipients with absent or minimal pericarditis symptoms at Week 16 of the randomized withdrawal period was 81% compared to 25% for placebo recipients. Consistent results were observed at Week 8 and Week 24 and were also highly statistically significant. Rilonacept was well-tolerated in the study, with adverse events consistent with the FDA-approved label for the treatment of Cryopyrin-Associated Periodic Syndromes. The most common adverse events were injection site reactions. Additional analyses of the RHAPSODY trial results are ongoing, and Kiniksa plans to present the data at a future medical meeting or in a publication. Rilonacept was discovered and developed by Regeneron Pharmaceuticals (REGN) and is approved by the FDA under the brand name ARCALYST for the treatment of CAPS. Kiniksa licensed rilonacept from Regeneron in 2017 for evaluation in diseases believed to be mediated by both IL-1alpha and IL-1beta, including recurrent pericarditis. The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019. Based on the Phase 3 RHAPSODY data announced today, the Biologic License Application (BLA) for CAPS will transfer to Kiniksa, and the company plans to submit an sBLA with the FDA in recurrent pericarditis later this year. Upon receipt of FDA approval for rilonacept in recurrent pericarditis, Kiniksa would assume the sales and distribution of rilonacept for the approved indications in the United States and will evenly split profits on sales with Regeneron.

ShowHide Related Items >><<
REGN Regeneron
$611.30 /

-8.81 (-1.42%)

KNSA Kiniksa
$23.04 /

-2.19 (-8.68%)

KNSA Kiniksa
$23.04 /

-2.19 (-8.68%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
REGN Regeneron
$611.30 /

-8.81 (-1.42%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
REGN Regeneron
$611.30 /

-8.81 (-1.42%)

KNSA Kiniksa
$23.04 /

-2.19 (-8.68%)

  • 27
    May
  • 14
    May
REGN Regeneron
$611.30 /

-8.81 (-1.42%)

REGN Regeneron
$611.30 /

-8.81 (-1.42%)

KNSA Kiniksa
$23.04 /

-2.19 (-8.68%)

REGN Regeneron
$611.30 /

-8.81 (-1.42%)

KNSA Kiniksa
$23.04 /

-2.19 (-8.68%)

Over a week ago
Initiation
Translate Bio initiated with a Buy at SunTrust » 07:27
06/26/20
06/26
07:27
06/26/20
07:27
TBIO

Translate Bio

$24.69 /

-2.04 (-7.63%)

, SNY

Sanofi

$51.85 /

+0.75 (+1.47%)

SunTrust analyst Joon Lee…

SunTrust analyst Joon Lee initiated coverage of Translate Bio (TBIO) with a Buy rating and $40 price target. The analyst notes that the mRNA is an "emerging therapeutic modality that could rival RNA silencing therapeutics", and he is positive on the company's early MRT5005 data in cystic fibrosis, which significantly de-risks three additional follow-on lung indications. Lee adds that Translate Bio's recent collaboration deal with Sanofi (SNY) is validating.

ShowHide Related Items >><<
TBIO Translate Bio
$24.69 /

-2.04 (-7.63%)

SNY Sanofi
$51.85 /

+0.75 (+1.47%)

TBIO Translate Bio
$24.69 /

-2.04 (-7.63%)

06/26/20 Citi
Translate Bio price target raised to $35 from $17 at Citi
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/25/20 Citi
Translate Bio price target raised to $35 from $17 at Citi
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
SNY Sanofi
$51.85 /

+0.75 (+1.47%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
TBIO Translate Bio
$24.69 /

-2.04 (-7.63%)

SNY Sanofi
$51.85 /

+0.75 (+1.47%)

  • 26
    Jun
  • 18
    Sep
SNY Sanofi
$51.85 /

+0.75 (+1.47%)

TBIO Translate Bio
$24.69 /

-2.04 (-7.63%)

SNY Sanofi
$51.85 /

+0.75 (+1.47%)

TBIO Translate Bio
$24.69 /

-2.04 (-7.63%)

SNY Sanofi
$51.85 /

+0.75 (+1.47%)

Periodicals
Sanofi mulls eliminating hundreds of jobs, Reuters reports » 10:27
06/25/20
06/25
10:27
06/25/20
10:27
SNY

Sanofi

$51.19 /

+0.09 (+0.18%)

Sanofi is mulling the…

Sanofi is mulling the elimination of hundreds of jobs and will discuss possible steps with staff representatives on Friday and Monday to develop a restructuring plan, Reuters' Matthias Blamont reports, citing four sources familiar with the matter. The move comes as the French drugmaker's CEO Paul Hudson has been looking to reduce costs. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.19 /

+0.09 (+0.18%)

SNY Sanofi
$51.19 /

+0.09 (+0.18%)

06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$51.19 /

+0.09 (+0.18%)

SNY Sanofi
$51.19 /

+0.09 (+0.18%)

SNY Sanofi
$51.19 /

+0.09 (+0.18%)

SNY Sanofi
$51.19 /

+0.09 (+0.18%)

Periodicals
Sanofi considers jobs cuts, will discuss with reps in coming days, Reuters says  10:15
06/25/20
06/25
10:15
06/25/20
10:15
SNY

Sanofi

$51.00 /

-0.1 (-0.20%)

 
ShowHide Related Items >><<
SNY Sanofi
$51.00 /

-0.1 (-0.20%)

SNY Sanofi
$51.00 /

-0.1 (-0.20%)

06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$51.00 /

-0.1 (-0.20%)

SNY Sanofi
$51.00 /

-0.1 (-0.20%)

SNY Sanofi
$51.00 /

-0.1 (-0.20%)

SNY Sanofi
$51.00 /

-0.1 (-0.20%)

Conference/Events
Markets and Markets to hold a virtual event » 09:46
06/25/20
06/25
09:46
06/25/20
09:46
ALLO

Allogene Therapeutics

$43.29 /

+ (+0.00%)

, CELG

Bought by BMY

$108.26 /

+ (+0.00%)

, MRK

Merck

$75.62 /

-0.22 (-0.29%)

, PFE

Pfizer

$32.09 /

-0.11 (-0.34%)

, QGEN

Qiagen

$43.07 /

+0.1 (+0.23%)

, REGN

Regeneron

$608.77 /

+3.675 (+0.61%)

, TAK

Takeda Pharmaceutical

$18.25 /

-0.08 (-0.44%)

Next-Gen 3rd Annual…

Next-Gen 3rd Annual Immuno-Oncology Virtual Congress will be held on June 25-26. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
CELG Bought by BMY
$108.26 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
MRK Merck
$75.62 /

-0.22 (-0.29%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
PFE Pfizer
$32.09 /

-0.11 (-0.34%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
REGN Regeneron
$608.77 /

+3.675 (+0.61%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.